December 18, 2025
NetraMark Holdings Inc.
ISIN: CA64119M1059
NetraMark Delivers Transformational Quarter of Execution
Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award Secured TORONTO, ON, December 18, 2025 – NetraMark Holdings Inc. (the...
Read more >>NetraMark Achieves Major FDA Milestone
TORONTO, ON, December 15, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced the completion of its Critical Path Innovation Meeting (CPIM)...
Read more >NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
TORONTO, ON, December 8, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that its peer-reviewed paper, “Explainable AI-Driven Precision Clinical Trial...
Read more >NetraMark Signs Four New Contracts with a Leading Global Pharmaceutical Company to Enhance Clinical Trial Insights
TORONTO, ON, November 18, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that it has signed four contracts with a leading global pharmaceutical company...
Read more >